Why the World's Biggest Hyaluronic Acid Maker Just Backed a TikTok Brand

LOS ANGELES, CA – November 09, 2026 — The architecture of the global beauty industry has long relied on a strict, unspoken separation of church and state: ingredient manufacturers synthesize the raw materials in massive industrial parks, and consumer brands market the finished serums and creams to the public. But a quiet operational shift is blurring those lines, signaling a new era of vertical integration that could redefine how prestige skincare is formulated, priced, and sold.

Enter Alaris, a newly minted Los Angeles-based skincare startup that officially launched on October 16. Today, the company announced an undisclosed investment from Bloomage Biotechnology Corporation. While early-stage beauty investments are commonplace, the strategic architecture of this specific deal is not. This transaction marks the first time Bloomage—the world's largest producer of hyaluronic acid—has backed a U.S.-founded skincare brand.

The Upstream Giant Goes Direct

To understand the strategic rationale of this deal, one must look at the behemoth backing it. Listed on the Shanghai Stock Exchange, Bloomage is not a traditional venture capital firm. It is a synthetic biology powerhouse that has pioneered the biomanufacturing of hyaluronic acid, commanding the number one global market share for the ingredient. For over two decades, the Chinese biotech giant has powered the formulations of the world's most prestigious skincare conglomerates, operating one of the largest synthetic biology manufacturing platforms spanning pharmaceuticals, medical aesthetics, and dermatology.

Yet, supplying raw materials—even at a massive global scale—inherently caps margin potential and distances the manufacturer from the end consumer. By taking an equity stake in an American indie brand, Bloomage secures a direct, proprietary pipeline to the Western consumer. It is a textbook example of downstream expansion, executed through venture backing rather than the costly endeavor of building a ground-up subsidiary in a foreign market.

"Bloomage Biotech has spent over two decades advancing hyaluronic acid science," said Yizheng Li, director, vice president and board secretary of Bloomage Biotech. "The U.S. is an important market for us, and Alaris brings our research to American shoppers through founders who know this market. We are proud to be its partner from day one."

Formulating for the Vanity Table

This partnership fundamentally alters the unit economics for the Los Angeles startup. Typically, emerging beauty brands face crippling minimum order quantities and exorbitant markups when sourcing cutting-edge active ingredients through third-party distributors. By partnering directly with its source, Alaris operates with a structural advantage: institutional-grade supply chain reliability and cost structures that are virtually impossible for independent competitors to replicate.

The brand’s "From Soil to Science" philosophy leans heavily on this advantage, pairing botanical extracts with advanced biotech ingredients. The debut product line reflects this high-science, low-cost advantage. Alaris launched with two specialized items, each priced at a highly accessible $20 per box of four: the Dual-Chamber Radiance Firming Mask and the Glacial Purple Clay Sheet Mask.

The firming mask features a unique two-piece design that hooks over the ears to target the jawline—an area frequently neglected by traditional sheet masks. It utilizes black goji, ergothioneine, and four distinct forms of synthetic biology-derived hyaluronic acid to visibly boost radiance and improve the look of firmness. Ergothioneine, a potent antioxidant amino acid, protects skin cells from oxidative damage, while the multi-weight hyaluronic acid ensures deep cellular hydration.

Meanwhile, the Glacial Purple Clay Sheet Mask offers manicouagan clay on a ready-to-wear sheet, eliminating the mess associated with traditional jarred clay masks. Formulated with sodium hyaluronate and zinc PCA, it is designed to absorb excess oil and refine the look of pores. Both products are formulated with sensitive skin in mind and are strictly not tested on animals.

Built for the Social Commerce Era

However, operational innovation extends beyond the supply chain; it also dictates distribution. Alaris is entirely bypassing legacy prestige retailers like Sephora and Ulta, opting instead for a distribution model engineered specifically for the modern creator economy. The brand is retailing exclusively through its proprietary website and TikTok Shop.

The founders' pedigrees perfectly explain this strategic pivot. Co-founder Cherrie Rao previously served as the head of global PR and brand communications at Florasis, a C-beauty giant that famously leveraged intricate aesthetics and aggressive social marketing to achieve massive international recognition. Her partner, co-founder Chelle Zeng, brings localized digital expertise as a creator-economy strategist who previously led social commerce at Pixi and Sacheu. Zeng also wields considerable personal influence, boasting an audience of 400,000 followers.

"Most people don't need a 10-step routine. They need a few products that earn their place," said Rao, articulating a philosophy of streamlined, highly efficacious regimens that resonates deeply with a consumer base fatigued by overly complex skincare routines.

This direct-to-consumer social approach drastically lowers customer acquisition costs. In an era where digital ad spend is yielding diminishing returns, having founders who natively understand TikTok's algorithmic commerce and possess built-in audiences is as valuable as the intellectual property inside the bottle.

Redefining the Indie Beauty Playbook

The Bloomage-Alaris deal is more than a standard capital injection; it is a blueprint for the future of cross-border consumer goods. As Chinese biotechnology firms look to expand their footprint and capture higher margins in the United States, backing savvy, culturally fluent local founders offers a low-friction entry point.

For the broader beauty industry, the implications are profound. If upstream suppliers continue to arm nimble, socially native startups with pharmaceutical-grade ingredients at preferential costs, the traditional moat enjoyed by legacy beauty conglomerates will rapidly evaporate.

As the startup prepares to expand its product line by year-end with a Peptide Glow Oil Serum, Ectoin Jelly Mist, and Rose PDRN Firming Balm Stick—featuring polydeoxyribonucleotide, a regenerative compound derived from salmon DNA—the market will be watching closely. Alaris is not just selling skincare; it is stress-testing a highly efficient, vertically integrated business model that could very well dictate the next decade of cosmetic retail.